Skip to content

Released Nov 4, 2019, after the close

10-Q filed Nov 4, 2019, 35 days after period end · 0001564590-19-039770

Q3 2019 · 10-Q
Revenue$172.00K−73.9% vs Q3 2018+156.7% vs Q2 2019
Net Income-$17.70MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.95N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$17,985,000N/M
Operating Cash Flowderived-$9,659,000N/M
Free Cash Flowderived-$9,676,000—
Margins · derived
Operating margin-10456.4%−8794.5 pt vs Q3 2018
Net margin-10290.7%−8700.6 pt vs Q3 2018

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017Q3 2016
Revenue$172.00K$658.00K$597.00K—
Net Income-$17.70M-$10.46M-$9.84M-$6.32M
EPS Diluted-$0.95-$0.60-$36.02-$23.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR